How cachexia affects lung cancer treatment with immune therapy
Official title: Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer
Funded at Ohio State University · NIH-10906306 · Data updated 2026-11-12
This study is looking at how severe weight loss and muscle loss, known as cachexia, affects the success of a lung cancer treatment called anti-PD1 therapy, to help find ways to make this treatment work better for patients dealing with both lung cancer and cachexia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 8, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $594,010 |
| NIH project number | 5R01CA273924-03 |
| Project ID | NIH-10906306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients who are experiencing cachexia.
✕Less likely to help
Patients without lung cancer or those who do not have cachexia may not benefit from this research.
What this research studies
This research investigates the impact of cachexia, a condition characterized by severe weight loss and muscle wasting, on the effectiveness of anti-PD1 therapy in lung cancer patients. The study aims to understand how cachexia alters immune responses and the clearance of therapeutic antibodies in the body. By examining both human patients and animal models, the researchers will explore the role of the neonatal Fc receptor (FcRn) in modulating immune responses and its potential influence on treatment outcomes. The goal is to identify mechanisms that could improve the effectiveness of immune therapies for patients suffering from lung cancer and cachexia.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients with cachexia, enhancing their response to immune therapies.
How similar studies have gone: Previous research has indicated that understanding the relationship between cachexia and immune response can lead to better treatment outcomes, suggesting potential success for this approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Phelps, Mitch a — Ohio State University
- Study coordinator: Phelps, Mitch a
Related research
Other NIH-funded projects on the same topics.
-
How cancer-related weight loss might change antibody recycling and affect anti–PD-1 therapy for lung cancer
Researchers are checking whether cancer-related weight loss changes how the body handles antibody drugs and makes anti–PD-1 treatments work less well for people with lung cancer.
-
Understanding weight loss in lung cancer patients
This study is looking at why people with lung cancer sometimes lose weight and muscle without trying, and it hopes to find new ways to help improve their health and well-being by understanding the changes happening in their bodies.
-
Creating a mouse model to understand and treat lung cancer-related weight loss
This study is creating a special type of mouse to help us understand the weight loss and muscle loss that lung cancer patients experience, so we can find better ways to help those who are struggling with these symptoms.
-
Mitochondrial pores and muscle loss in cancer cachexia
A small US-based study will explore how changes in mitochondria contribute to muscle wasting in people with cancer cachexia and how this may be slowed.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
CANCAN: A Virtual Institute to Cure Cancer Cachexia
A broad, collaborative NIH initiative aims to uncover why cancer patients lose weight and muscle and to develop new ways to treat this serious condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.